MHRA Guidelines on Individualized mRNA Cancer Immunotherapies
- Current development from Covid-19 mRNA/LNP vaccines to therapeutics
- Regulatory challenges posed for individualised mRNA cancer immunotherapies
- An overview of the key aspects currently considered on the regulations, manufacturing, pre-clinical, clinical and post-authorisation for individualised mRNA-based cancer immunotherapies